Seeking Alpha

Oncothyreon (ONTY +16%) is higher today on a rumor that Phase III results of its cancer...

Oncothyreon (ONTY +16%) is higher today on a rumor that Phase III results of its cancer treatment drug Stimuvax are meeting endpoints. The stock has been heavily shorted recently - short interest now averages 2+ days to cover - adding to the stock's volatility.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|